• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异常凝血酶原(PIVKA-Ⅱ)与甲胎蛋白(AFP)在肝细胞癌诊断及术后变化监测中的价值比较

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma.

作者信息

Lee Qiuyan, Yu Xixiang, Yu Weiwei

机构信息

Wenzhou Medical University, Wenzhou, China.

Interventional Vascular surgery, Wenzhou people's Hospital, China.

出版信息

J Interv Med. 2021 Mar 16;4(2):77-81. doi: 10.1016/j.jimed.2021.02.004. eCollection 2021 May.

DOI:10.1016/j.jimed.2021.02.004
PMID:34805952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8562275/
Abstract

OBJECTIVE

To explore the diagnostic value of abnormal prothrombin Ⅱ (PIVKA-Ⅱ) and alpha-fetoprotein (AFP) in primary hepatocellular carcinoma (HCC).

METHODS

From 2018 0.01 to 2020.01, there were 158 patients with primary liver cancer caused by chronic hepatitis B (male 116, women 42) and 62 patients with chronic hepatitis B (male 34, female 28). The levels of serum PIVKA-Ⅱ and AFP were measured, and the results were statistically analyzed.

RESULTS

The value of PIVKA-Ⅱin liver cancer group was distinctly higher than that in chronic viral hepatitis B group, the difference is statistically significant (P ​< ​0.05). So does the value of AFP. Draw the subject working characteristic curve (ROC curve), the area under the curve of AFP and PIVKA-Ⅱ is 0.799 and 0.836, and that of the combination of AFP and PIVKA-Ⅱ is 0.854, the sensitivity is 57.6%,68.4%,72.2%,respectively, the specificity is 93.5%, 98.4%, 96.8%, respectively. After operation or interventional therapy, the value of PIVKA-Ⅱ in liver cancer group was clearly lower than that before treatment, and the difference was statistically significant.

CONCLUSION

In the diagnostic value of primary liver cancer, PIVKA-II combined with AFP is higher than PIVKA-II, while AFP has the lowest benefit. We also find that PIVKA-II has higher disease monitoring value than AFP.

摘要

目的

探讨异常凝血酶原Ⅱ(PIVKA-Ⅱ)和甲胎蛋白(AFP)在原发性肝细胞癌(HCC)中的诊断价值。

方法

选取2018年1月1日至2020年1月1日期间的158例慢性乙型肝炎所致原发性肝癌患者(男性116例,女性42例)以及62例慢性乙型肝炎患者(男性34例,女性28例)。检测血清PIVKA-Ⅱ和AFP水平,并对结果进行统计学分析。

结果

肝癌组PIVKA-Ⅱ值明显高于慢性乙型病毒性肝炎组,差异具有统计学意义(P<0.05)。AFP值亦是如此。绘制受试者工作特征曲线(ROC曲线),AFP和PIVKA-Ⅱ的曲线下面积分别为0.799和0.836,AFP与PIVKA-Ⅱ联合检测的曲线下面积为0.854,敏感性分别为57.6%、68.4%、72.2%,特异性分别为93.5%、98.4%、96.8%。手术或介入治疗后,肝癌组PIVKA-Ⅱ值明显低于治疗前,差异具有统计学意义。

结论

在原发性肝癌的诊断价值方面,PIVKA-II联合AFP高于PIVKA-II,而AFP单独检测的诊断效能最低。我们还发现,PIVKA-II在疾病监测方面的价值高于AFP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/22c8def5320d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/c32511a6093b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/d4d7a6fdc7cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/071e3e76eeda/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/23105ce8ad43/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/22c8def5320d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/c32511a6093b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/d4d7a6fdc7cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/071e3e76eeda/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/23105ce8ad43/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4829/8562275/22c8def5320d/gr5.jpg

相似文献

1
The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma.异常凝血酶原(PIVKA-Ⅱ)与甲胎蛋白(AFP)在肝细胞癌诊断及术后变化监测中的价值比较
J Interv Med. 2021 Mar 16;4(2):77-81. doi: 10.1016/j.jimed.2021.02.004. eCollection 2021 May.
2
[Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].血清甲胎蛋白、甲胎蛋白变异体及异常凝血酶原在原发性肝细胞癌中的诊断价值
Zhonghua Gan Zang Bing Za Zhi. 2019 Aug 20;27(8):634-637. doi: 10.3760/cma.j.issn.1007-3418.2019.08.009.
3
Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.甲胎蛋白异质体 3 和异常凝血酶原在总甲胎蛋白指导下对肝细胞癌的诊断价值。
World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.
4
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.异常凝血酶原和甲胎蛋白在乙型肝炎病毒相关性肝细胞癌中的诊断价值
World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.
5
Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.血清 AFP 和 PIVKA-II 对肝细胞癌的诊断、治疗和预后的临床价值。
J Clin Lab Anal. 2023 Jan;37(1):e24823. doi: 10.1002/jcla.24823. Epub 2022 Dec 29.
6
Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.评价血清 GDF15、AFP 和 PIVKA-II 作为乙型肝炎病毒相关肝细胞癌的诊断标志物。
Lab Med. 2021 Jul 1;52(4):381-389. doi: 10.1093/labmed/lmaa089.
7
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.血清 PIVKA-II 水平对 BCLC 早期肝细胞癌的诊断价值及其与 HBV DNA 的相关性。
Cancer Biomark. 2018;23(2):235-242. doi: 10.3233/CBM-181402.
8
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.基于 miR-122、AFP 和 PIVKA-II 联合检测评估 HBV 肝硬化患者肝细胞癌风险。
Panminerva Med. 2017 Dec;59(4):283-289. doi: 10.23736/S0031-0808.17.03353-5. Epub 2017 Jun 23.
9
PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.PIVKA-II 可作为 AFP 的补充生物标志物,用于肝癌的诊断。
BMC Cancer. 2021 Apr 13;21(1):401. doi: 10.1186/s12885-021-08138-3.
10
Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.维生素K缺乏或拮抗剂-II诱导的凝血酶原(PIVKA-II)对早期HBV相关肝细胞癌的诊断价值
Infect Agent Cancer. 2017 Aug 23;12:47. doi: 10.1186/s13027-017-0153-6. eCollection 2017.

引用本文的文献

1
Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma.细胞因子诱导的杀伤细胞免疫疗法可降低早期肝细胞癌患者的复发率。
Cancers (Basel). 2025 Feb 7;17(4):566. doi: 10.3390/cancers17040566.
2
The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.肝细胞癌精准治疗和临床药物选择的细胞死亡相关基因机器学习模型。
J Cell Mol Med. 2024 Apr;28(7):e18168. doi: 10.1111/jcmm.18168.
3
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.

本文引用的文献

1
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].《中国原发性肝癌诊疗规范(2019年版)》
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
2
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.异常凝血酶原作为肝细胞癌潜在的新型生物标志物——一项初步研究
In Vivo. 2018 Nov-Dec;32(6):1551-1554. doi: 10.21873/invivo.11413.
3
Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma.
前瞻性队列研究中用于检测 HCC 的新型算法评分(GAAD)的开发和临床验证。
Hepatol Commun. 2023 Nov 8;7(11). doi: 10.1097/HC9.0000000000000317. eCollection 2023 Nov 1.
4
[Individualized curative treatment for malignant diseases through liver transplantation].[通过肝移植对恶性疾病进行个体化治疗]
Chirurgie (Heidelb). 2024 Feb;95(2):122-128. doi: 10.1007/s00104-023-01973-z. Epub 2023 Oct 17.
5
Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.维生素K缺乏或拮抗剂-II诱导蛋白与甲胎蛋白在肝细胞癌诊断中的比较:一项Meta分析的系统评价
J Clin Med Res. 2023 Jul;15(7):343-359. doi: 10.14740/jocmr4951. Epub 2023 Jul 12.
6
Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.甲基化 SEPT9 联合 AFP 和 PIVKA-II 可有效检测高危人群 HCC。
BMC Gastroenterol. 2023 Jul 31;23(1):260. doi: 10.1186/s12876-023-02900-6.
7
Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.多纳非尼与仑伐替尼治疗中晚期肝细胞癌的临床疗效比较。
Am J Transl Res. 2023 May 15;15(5):3579-3585. eCollection 2023.
8
Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model.肝细胞癌危险因素分析及临床预后模型的建立
Front Oncol. 2023 Mar 22;13:1067353. doi: 10.3389/fonc.2023.1067353. eCollection 2023.
9
Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.维生素K缺乏诱导的肝细胞癌肝外蛋白的诊断性能:一项系统评价和荟萃分析
Diagnostics (Basel). 2023 Feb 21;13(5):816. doi: 10.3390/diagnostics13050816.
10
PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients.异常凝血酶原或甲胎蛋白在高危患者的肝细胞癌诊断中具有更好的诊断特性。
J Circ Biomark. 2023 Feb 17;12:12-16. doi: 10.33393/jcb.2023.2453. eCollection 2023 Jan-Dec.
脱羧凝血酶原联合甲胎蛋白对原发性肝癌的诊断价值。
Biosci Rep. 2018 Oct 5;38(5). doi: 10.1042/BSR20180044. Print 2018 Oct 31.
4
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.日本肝细胞癌的管理:日本肝脏学会(JSH)2010 年更新版提出的基于共识的临床实践指南。
Dig Dis. 2011;29(3):339-64. doi: 10.1159/000327577. Epub 2011 Aug 9.
5
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.去γ-羧基(异常)凝血酶原作为原发性肝细胞癌的血清标志物
N Engl J Med. 1984 May 31;310(22):1427-31. doi: 10.1056/NEJM198405313102204.